Psoriatic Arthritis Quality of Life

The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient’s quality of life.[1]

It is a self-administered, 20-item questionnaire that takes about three minutes to complete.[2] The answers are restricted to true or false.[3]

Development

The PsAQoL was first published in 2004 by Galen Research. The development of the measure was a joint effort between Galen Research, the University of Leeds and St. Vincent’s University Hospital in Dublin. The study was funded by the Arthritis Research Campaign in the UK.[2]

Qualitative interviews were conducted with 48 patients, after which a 51-item questionnaire was created. A follow up survey with 94 patients was then conducted which reduced the items to 35. An additional 286 patients were surveyed and Rasch analysis was performed, which finalized the PsAQoL to 20 items.[4] A high score on the PsAQoL indicates a lower quality of life.

International Use

The Psoriatic Arthritis Quality of Life measure has been translated into 30 languages, other than UK English.[5] These languages include Dutch[6] and Swedish.[7] The PsAQoL has also been utilized in clinical research studies in order to determine whether a medication or treatment is effective in treating psoriatic arthritis. If the scores on the PsAQoL change after treatment, this means that the given treatment has had an effect on quality of life. The PsAQoL has been used to evaluate infliximab[8] and adalimumab.[9]

References

  1. ↑ Brodszky, V; Pentek, M; Balint, PV; Geher, P; Hajdu, O; Hodinka, L; Horvath, G; Koo, E; Polgar, A; Sesztak, M; Szanto, S; Ujfalussy, I; Gulacsi, L (August 2010). "Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey". Scandinavian Journal of Rheumatology. 39 (4): 303–309. doi:10.3109/03009740903468982. PMID 20166848. Retrieved 9 October 2013.
  2. 1 2 McKenna, S; Doward, L; Whalley, D; Tennant, A; Emery, P; Veale, D (February 2004). "Development of the PsAQoL: a quality of life instrument specific to psoriatic arthritis". Annals of Rheumatic Diseases. 63 (2): 162–169. doi:10.1136/ard.2003.006296. PMC 1754880Freely accessible. PMID 14722205.
  3. ↑ Roussou, Euthalia; Chopra, Sunil; Ngandu, Danny Lunda (2013). "Phenotypic and clinical differences between Caucasian and South Asian patients with psoriatic arthritis living in North East London". Clinical Rheumatology. 32 (5): 591–599. doi:10.1007/s10067-012-2139-5. PMID 23247553. Retrieved 9 October 2013.
  4. ↑ Mease, Philip J. (November 2011). "Measures of Psoriatic Arthritis". Arthritis Care & Research. 63 (S11): S64–S85. doi:10.1002/acr.20577. PMID 22588772. Retrieved 9 October 2013.
  5. ↑ "Measures Database". Galen-Research.com. Galen Research. Retrieved 9 October 2013.
  6. ↑ Wink, Freke; Arends, Suzanne; McKenna, Stephen P.; Houtman, Pieternella M.; Brouwer, Elisabeth; Spoorenberg, Anneke (2013). Kuwana, Masataka, ed. "Validity and Reliability of the Dutch Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) Questionnaire". PLoS ONE. 8 (2): e55912. doi:10.1371/journal.pone.0055912. PMC 3572180Freely accessible. PMID 23418474. Retrieved 9 October 2013.
  7. ↑ Billing, E; McKenna, SP; Staun, M; Lindqvist, U (May 2010). "Adaptation of the Psoriatic Arthritis Quality of Life (PsAQoL) instrument for Sweden". Scandinavian Journal of Rheumatology. 39 (3): 223–228. doi:10.3109/03009740903347975. PMID 20063984. Retrieved 9 October 2013.
  8. ↑ Marzo-Ortega, Helena; McGonagle, Dennis; Rhodes, Laura A; Tan, Ai Lyn; Conaghan, Philip G; O'Connor, Philip; Tanner, Steven F.; Fraser, Alexander; Veale, Douglas; Emery, Paul (2007). "Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis". Annals of Rheumatic Diseases. 66 (6): 778–781. doi:10.1136/ard.2006.063818. PMC 1954680Freely accessible. PMID 17185324. Retrieved 9 October 2013.
  9. ↑ "A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)". ClinicalTrials.gov. Abbott. Retrieved 9 October 2013.
This article is issued from Wikipedia - version of the 7/16/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.